Disability and Adverse Effects of Oral Versus Long-Acting Injectable Antipsychotics in Schizophrenia-Spectrum and Bipolar Disorder: A Comparison Based on Data-Driven Taxonomy
Clinical Drug Investigation · 2024-09 · 44 (9) · 715-727
DOI: 10.1007/s40261-024-01391-x ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Drug Investigation, online erschienen am 20.09.2024. Verfasst von Alessandro Rodolico und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Psychotherapy, TUM School of Medicine and Health, Technical University of Munich, Klinikum rechts der Isar, Munich, Germ…. Hauptthemen laut MEDLINE: Antipsychotic Agents, Schizophrenia, Bipolar Disorder, Delayed-Action Preparations. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
BACKGROUND: Patients undergoing antipsychotic treatment for psychiatric disorders may experience challenges in functioning, either stemming from the severity of the illness or from the tolerability issues of prescribed medications. OBJECTIVES: The aims of this cross-sectional study are to investigate the impact of adverse effects of antipsychotic drugs on patients' daily life functioning, comparing oral and long-acting injectable (LAI) antipsychotics, and further dividing antipsychotics by receptor-binding profiles based on recently defined data-driven taxonomy. METHODS: This study involved patients with schizophrenia and bipolar spectrum disorders taking oral or LAI antipsychotics. Disability and functioning levels were assessed using the World Health Organization Disability Assessment Schedule 2.0 (WHODAS), and the adverse effects of medications were evaluated using the Udvalg for Kliniske Undersogelser (UKU) Side Effect Rating Scale and its subscales. RESULTS: The total sample consisted of 126 participants with a diagnosis of schizophrenia-spectrum or bipolar disorder, and included 54 males and 72 females ranging from 18 to 78 years of age (mean 45.1, standard deviation 14); 78 patients were taking oral antipsychotics and 48 were taking LAI antipsychotics, with subcategories of muscarinic (31), adrenergic/low dopamine (25), serotonergic/dopaminergic (23), dopaminergic (1), LAI muscarinic (15), LAI adrenergic (6), and LAI serotonergic/dopaminergic (25). The UKU total score for adverse effects showed significant correlations with WHODAS total score (ρ = 0.475; p < 0.001). Compared with oral antipsychotics, LAIs showed significantly lower scores in psychological (p = 0.014), autonomic (p = 0.008), other (p = 0.004), and sexual adverse effects (p = 0.008), as well as the UKU total score (p = 0.002). The Kruskal-Wallis test showed a significant difference in adverse effects between LAI and oral muscarinic subgroups, with LAIs having lower scores compared with antipsychotics binding to muscarinic receptors (p = 0.043). CONCLUSION: These findings indicate clinically relevant differences in adverse effects among formulations, warranting further investigation for future observational studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry and Psychotherapy, TUM School of Medicine and Health, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany.
- Section of Psychology, Department of Educational Sciences, University of Catania, Via Teatro Greco 84, 95124, Catania, Italy.
- Psychiatry Unit, Department of Clinical and Experimental Medicine, University of Catania, Via Santa Sofia 78, 95123, Catania, Italy. pierfelicecutrufelli@yahoo.it.
- Psychiatry Unit, Department of Clinical and Experimental Medicine, University of Catania, Via Santa Sofia 78, 95123, Catania, Italy.
- Oasi Research Institute, IRCCS, Via Conte Ruggero 73, 94018, Troina, Italy.
- Department of Drug and Health Sciences, University of Catania, Via Valdisavoia, 5, 95123, Catania, Italy.
Zitieren
APA
Rodolico, A., Aprile, S. F., Cutrufelli, P., Privitera, G., Castellano, S., Concerto, C., Furnari, R., Guerrera, C. S., Mineo, L., Platania, G. A., Petralia, A., Caraci, F., & Signorelli, M. S. (2024). Disability and Adverse Effects of Oral Versus Long-Acting Injectable Antipsychotics in Schizophrenia-Spectrum and Bipolar Disorder: A Comparison Based on Data-Driven Taxonomy. Clinical Drug Investigation, 44(9), 715-727. https://doi.org/10.1007/s40261-024-01391-x
Vancouver
Rodolico A, Aprile SF, Cutrufelli P, Privitera G, Castellano S, Concerto C, et al. Disability and Adverse Effects of Oral Versus Long-Acting Injectable Antipsychotics in Schizophrenia-Spectrum and Bipolar Disorder: A Comparison Based on Data-Driven Taxonomy. Clinical Drug Investigation. 2024;44(9):715-727. doi:10.1007/s40261-024-01391-x
BibTeX
@article{Rodolico2024,
author = {Rodolico, Alessandro and Aprile, Sofia Francesca and Cutrufelli, Pierfelice and Privitera, Gabriele and Castellano, Sabrina and Concerto, Carmen and Furnari, Rosaria and Guerrera, Claudia Savia and Mineo, Ludovico and Platania, Giuseppe Alessio and Petralia, Antonino and Caraci, Filippo and Signorelli, Maria Salvina},
title = {Disability and Adverse Effects of Oral Versus Long-Acting Injectable Antipsychotics in Schizophrenia-Spectrum and Bipolar Disorder: A Comparison Based on Data-Driven Taxonomy},
journal = {Clinical Drug Investigation},
year = {2024},
volume = {44},
number = {9},
pages = {715--727},
doi = {10.1007/s40261-024-01391-x}
}
EUVIMED